S1 Ep8: Part 1 Of 5: Top 10 Oncogenic Markers In NSCLC For 2022: An Interview With Dara Aisner MD, PhD PER Spectives podcast

Artwork

Science Biology Podcasting Education Medicine Spectives

Indhold leveret af PER Spectives and PER® Spectives. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af PER Spectives and PER® Spectives eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

PER Spectives « »
S1 Ep8: Part 1 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Dara Aisner MD, PhD

2y ago 18:02

Del

MP3•Episode hjem

Indhold leveret af PER Spectives and PER® Spectives. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af PER Spectives and PER® Spectives eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.
This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

… continue reading

27 episoder

#Science #Biology #Podcasting Education #Medicine #Spectives

Artwork

S1 Ep8: Part 1 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Dara Aisner MD, PhD

published 2y ago

Del

MP3•Episode hjem

Indhold leveret af PER Spectives and PER® Spectives. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af PER Spectives and PER® Spectives eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.
This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

… continue reading

27 episoder

#Science #Biology #Podcasting Education #Medicine #Spectives

All episodes

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner